title: Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
abstract: By using the hepatitis B core (HBc) protein gene as a carrier, HIV-1 env V3 gene was inserted into the carrier gene, and the HIV gene was expressed inside a chimeric HIV-HBc particle (HIV-HBc), which was a unique candidate for induction of HIV-specific CTL activity. This was seen significantly in mice without the need of an adjuvant, because other responses specific for the HIV peptide such as T-cell proliferation and antibody production were not induced. However, when hemagglutinating virus of Japan (HVJ) protein was incorporated into an anionic liposome containing HIV peptide (HIV-HVJ-liposome) and was used as a booster immunization in HIV-HBc primed animals, the HIV-specific T-cell response and enhanced CTL activity were clearly induced in consecutively immunized animals. Furthermore, the HIV-specific humoral immune response was also induced and a neutralization activity was detected in the immune sera. Thus, when an HIV peptide antigen is expressed inside the virus like a particle of HBc, it can induce both cellular and humoral immunities when an HVJ-HIV-liposome, but not an HIV-liposome, is inoculated as the booster antigen. The HVJ-stimulated splenocytes secreted IL-18 and IL-12 to synergistically enhance the secretion of IFN-gamma in vitro. These findings suggest that the HVJ protein is effective at inducing the HIV-specific immunities, if used as part of a booster antigen in the consecutive immunization regimen.
authors.affiliation: AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takeda
authors.forename: Kouichi
authors.initials: K
authors.lastname: Shiosaki
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Kaneda
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Nakasatomi
authors.forename: Hitomi
authors.initials: H
authors.lastname: Yoshizaki
authors.forename: Kenji
authors.initials: K
authors.lastname: Someya
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Konno
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Eda
authors.forename: Youichirou
authors.initials: Y
authors.lastname: Kino
authors.forename: Naoki
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Honda
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000592:standards; D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006168:Guinea Pigs; D015483:HIV Antibodies / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006512:Hepatitis B Core Antigens / Q000235:genetics / Q000276:immunology; D007114:Immunization / Q000379:methods; D007371:Interferon-gamma / Q000096:biosynthesis; D007378:Interleukins / Q000096:biosynthesis; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D029082:Sendai virus / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D006512:Hepatitis B Core Antigens; D007378:Interleukins; D008081:Liposomes; D011993:Recombinant Fusion Proteins; D007371:Interferon-gamma